Patent · US Expired

Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

US7208508B2 · kind B2 · utility

3Cited by

7References

1Claims

0Family size

Assignee

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

Juergen Daemmgen · Ochsenhausen, DE
Brian Guth · Warthausen, DE
Randolph Seidler · Eckenroth, DE

Key dates

Filing date	Apr 7, 2001
Grant date	Apr 24, 2007
Priority date	—
Expiry date	Apr 7, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the new use of bradycardiac substances such as a Ca++ channel blocker, beta-receptor blocker or if channel blocker, the if channel blockers being preferred, optionally in combination with a cardioactive substance for inducing the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.